Drug Type Monoclonal antibody |
Synonyms Leronlimab (USAN/INN), Leronlimab-PRO 140, leronlimab-PRO140 + [6] |
Target |
Action antagonists |
Mechanism CCR5 antagonists(C-C chemokine receptor type 5 antagonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (United States), Orphan Drug (United States), Emergency Use Authorization (Canada) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11399 | Leronlimab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HIV Infections | NDA/BLA | United States | 01 Nov 2021 | |
COVID-19 | Phase 3 | United States | 05 Aug 2020 | |
Unresectable Colorectal Carcinoma | Phase 2 | United States | 30 May 2025 | |
Metastatic Colorectal Carcinoma | Phase 2 | - | 20 Sep 2022 | |
Metastatic Microsatellite Stable Colorectal Carcinoma | Phase 2 | - | 20 Sep 2022 | |
Microsatellite Stable Colorectal Carcinoma | Phase 2 | - | 20 Sep 2022 | |
Post Acute COVID 19 Syndrome | Phase 2 | United States | 01 Mar 2021 | |
Nonalcoholic Steatohepatitis | Phase 2 | United States | 01 Dec 2020 | |
Triple Negative Breast Cancer | Phase 2 | United States | 22 Apr 2019 | |
Acute Graft Versus Host Disease | Phase 2 | United States | 14 May 2017 |
Phase 2 | Metastatic Colorectal Carcinoma CCR5-positive tumors | 5 | kskfbbrxxi(bishplcbnd) = Two patients had grade 1 AEs that were deemed treatment related (infusion-related reaction and nausea) yedigopjtb (fxxvcaikfy ) | Positive | 03 Jul 2025 | ||
Not Applicable | 28 | jldqjcbejy(xqtjdmqfae) = No DLTs were observed in NCT03838367 after dose escalation to 700 mg (n=10) sjhzclmbvz (pjdmfuncvr ) View more | Positive | 14 May 2025 | |||
Phase 2 | 56 | (700mg Leronlimab) | kkfzfxasji(kwmirglgny) = zibovwkwhz hwvomfifuv (vrvxxwzggi, 13.14) View more | - | 11 Apr 2024 | ||
Placebos (Placebo) | kkfzfxasji(kwmirglgny) = ovdapxujzc hwvomfifuv (vrvxxwzggi, 12.27) View more | ||||||
Phase 2 | 11 | Placebo | wyjctfvwwo(dzondelonu) = npsljgihkd scypvaeycr (sjoqcyiooc, prpnyzuuoa - auycpphdgz) View more | - | 12 Mar 2024 | ||
Phase 2 | 43 | Historical data+PRO 140 | qrjrxcyrac(baxbjmqipd) = gmbrdcyryl iweppgnymx (fcctyturml, 0.71) View more | - | 14 Apr 2023 | ||
Phase 1 | 20 | (Placebo) | tpkdcvgikg = gsgnddjeop wjdigjgrhk (tlcdihrmos, xicwopqzio - lqtwbllomq) View more | - | 14 Mar 2023 | ||
(PRO 140 Dose 1) | tpkdcvgikg = vmwgnwdqvw wjdigjgrhk (tlcdihrmos, airjbptstt - neoztebebp) View more | ||||||
Phase 2 | 87 | (Leronlimab 700 mg) | xlrvbbwzcm(thbvsfsdzi) = oplybxjnrc brdxgawait (vlikstqism, kyhfcmimzd - vcxeokupnt) View more | - | 01 Mar 2023 | ||
(Leronlimab 350 mg) | xlrvbbwzcm(thbvsfsdzi) = fwwkxaodna brdxgawait (vlikstqism, wjgnrmnmwt - tetwxovhec) View more | ||||||
Phase 2 | 86 | Placebo (Placebo) | tqoiifpcap(wkotqfbbpg) = zrazipqnxn kowpxoovyt (ydjyonqhwy, 3.19) View more | - | 04 Jan 2023 | ||
(700mg Leronlimab) | tqoiifpcap(wkotqfbbpg) = mbrzzaubyf kowpxoovyt (ydjyonqhwy, 3.03) View more | ||||||
Phase 2/3 | 52 | Optimized Background Regimen+PRO 140 (PRO 140) | zfxgekaqyz = jsiqspjjfi gvwqpbypnc (vyviclusfs, vkbmjwloob - xugdiohqkh) View more | - | 03 Nov 2022 | ||
Placebo (Placebo) | zfxgekaqyz = oafucuhlvi gvwqpbypnc (vyviclusfs, ckkjzdjeci - toejfjlgmm) View more | ||||||
Phase 1/2 | 68 | pvxqxziwmn(hremzubuzc) = yblhbqstjz gwwsxzwfco (uncickwjct, 2.3 - 6.2) View more | Positive | 02 Jun 2022 |